Who is sponsoring NCT07536191?

NCT07536191 is sponsored by Aichi Medical University.

What drugs are being tested in NCT07536191?

Interventions in NCT07536191: Endoscopic Ultrasound-Guided Gallbladder Drainage, Endoscopic Transpapillary Gallbladder Drainage.

What condition does NCT07536191 study?

NCT07536191 studies Acute Calculous Cholecystitis.

Is NCT07536191 still recruiting?

NCT07536191 is currently recruiting now. Last updated 17 April 2026.

Last reviewed 2026-04-17 · How we verify

NCT07536191: GALLVIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GALLVIA Trial: EUS-Guided vs Transpapillary Gallbladder Drainage for Acute Calculous Cholecystitis

Recruiting now NA Last updated 17 April 2026

What this trial tests

NA trial testing Endoscopic Ultrasound-Guided Gallbladder Drainage in Acute Calculous Cholecystitis in 90 participants. Currently enrolling.

Timeline

15 April 2026

Primary endpoint
31 December 2027

31 December 2030

Quick facts

Lead sponsor	Aichi Medical University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	15 April 2026
Primary completion	31 December 2027
Estimated completion	31 December 2030
Sites	5 locations across Japan

Drugs / interventions tested

Endoscopic Ultrasound-Guided Gallbladder Drainage
Endoscopic Transpapillary Gallbladder Drainage

Conditions studied

Acute Calculous Cholecystitis — all drugs for Acute Calculous Cholecystitis →

Sponsor

Aichi Medical University

Who can join

18 and older, any sex, with Acute Calculous Cholecystitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multicenter, prospective, open-label, randomized controlled trial compares endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) with endoscopic transpapillary gallbladder drainage (EGBS) in poor surgical candidates with acute calculous cholecystitis. Eligible patients will be randomized in a 1:1 ratio to undergo either EUS-GBD using a lumen-apposing metal stent or EGBS using a transpapillary plastic stent. The primary endpoint is clinical success, defined as successful gallbladder drainage with subsequent improvement of acute cholecystitis without the need for additional gallbladder drainage. Secondary endpoints include technical success, adverse events, reintervention rate, procedure time, length of hospital stay, and 30-day mortality. The trial aims to determine whether EUS-GBD provides superior clinical outcomes compared with EGBS in this high-risk population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Aichi Medical University trials

Trials by the same sponsor.

NCT07235007 — Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic C · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07536191 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aichi Medical University
Last refreshed: 17 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07536191.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing